Treating Hyperinsulinemia with Momordica charantia
|Department of Endocrinology, Ghent University Hospital, Belgium|
|Corresponding Author :||Prof. Frank Comhaire
Brakelmeersstraat, 18 B9830 Sint Martens-Latem, Belgium
Tel: +32 475 618 555
E-mail: [email protected]
|Received: May 15, 2015; Accepted: June 30, 2015; Published: July 5, 2015|
|Citation: Comhaire F (2015) Treating Hyperinsulinemia with Momordica charantia. J Metabolic Synd 4:177. doi:10.4172/2167-0943.1000177|
|Copyright: © 2015 Comhaire. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Objectives: To assess the efficacy of a novel nutraceutical mainly containing the extract of bitter gourd (Momordica charantia) and α-lipoic acid for the treatment of patients with hyperinsulinemia.
Methods: Pilot prospective open-label cohort trial including 11 patients with hyperinsulinemia due to insulin resistance. The concentrations of insulin, C-peptide, glucose, haemoglobin A1c, total cholesterol, triglycerids, gamma- glutamyltransferase, and C-reactive protein were measured in blood take between 3 and 4 hours after dinner.
Results: One and 4 months after initiation of treatment there was a significant decrease of the concentrations of Insulin (to average 25% of initial value), C-peptide (to average 44% of initial value), glucose, hemoglobin A1c and gamma-glutamyl transpeptidase. Clinical significance: Treatment of patients with hyperinsulinemia, with or without diabetes or metabolic syndrome, using a novel nutraceutical containing Momordica charantia and α-lipoic acid dramatically reduced insulin resistance and may have improved non-alcoholic fatty liver disease.